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Summary
Background:  Clostridium  difﬁcile  infection  is  the  leading  cause  of  gastroenteritis-
associated  deaths  in  the  industrialized  world,  followed  by  infection  with  norovirus.
Methods:  Using  a  cohort  study  design,  we  compared  90  inpatients  with  diarrhea  due
to  C.  difﬁcile  infection  (CDI)  with  180  inpatients  with  diarrhea  due  to  other  infectious
agents  (including  55%  with  norovirus  infection)  with  respect  to  complications  and  all-
cause  mortality.  The  effects  of  age,  severity  of  underlying  diseases  and  additional
infections  were  assessed  by  stratiﬁed  analyses.
Results:  Diarrhea  recurrence  occurred  8.9  (95%CI:  2.9—27.3)  times  more  often  in
CDI  independent  of  age  and  severity  of  comorbidities.  The  all-cause  mortality  in
CDI  patients  pre-discharge  and  at  30  and  180  days,  respectively,  was  20.0%,  17.0%
and  42.3%  versus  7.2%,  6.7%  and  22.5%  in  non-CDI  diarrhea  patients.  Among  those
patients  with  low  comorbidities,  who  were  younger  than  65  years  and  without  addi-
tional  infections,  the  all-cause  pre-discharge,  30-day  and  180-day  mortality  risks
were  signiﬁcantly  higher  for  the  CDI  diarrhea  patients  than  the  non-CDI  diarrhea
patients.  This  association  was  not  observed  among  patients  with  an  older  age,  more
severe  comorbidities  or  additional  infections.
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Introduction
Over  the  past  decade,  Clostridium  difﬁcile  infec-
tion (CDI)  has  evolved  to  become  the  primary
contributor to  healthcare-associated  infectious
diarrhea. The  infection  with  C.  difﬁcile  and  the
diarrheic agent,  norovirus,  are  the  leading  causes
of gastroenteritis-associated  deaths  in  the  indus-
trialized  world  [1,2]. A  5-year  literature  review  of
all-cause  mortality  in  European  and  North  Ameri-
can  hospital  patients  with  CDI  by  Mitchell  et  al.
revealed  a  pre-discharge  mortality  ranging  from
8% to  37%  and  a  30-day  mortality  ranging  from
9% to  38%  [3]. Risk  factors  associated  with  the
increased risk  of  CDI-related  mortality  include
older age  and  severe  comorbidities  [4—7].  In
the industrialized  world,  norovirus,  Campylobacter
spp., non-typhoidal  Salmonella  spp.,  diarrheagenic
Escherichia coli,  Yersinia  enterocolitica,  Shigella
spp.,  rotavirus  and  adenovirus  are  the  leading
causes of  infectious  diarrhea  in  addition  to  C.  dif-
ﬁcile, with  case  fatality  usually  ranging  between
0.01% and  1%  [8].
The  aim  of  our  study  was  to  compare  the  risk  of
complications, sequelae  and  pre-discharge,  30-day
and 180-day  all-cause  mortality  between  hospi-
tal patients  with  diarrhea  due  to  CDI  and  those
with diarrhea  due  to  other  infectious  agents  while
considering age,  severity  of  comorbidities  and  any
additional  infection  present  during  the  hospital  stay
as putative  confounders  or  effect  modiﬁers.
Materials and methods
Study design and study population
We  conducted  a  prospective,  hospital-based  cohort
study among  patients  with  infectious  diarrhea  in
a 777-bed  community  hospital  in  Vienna,  Austria
to investigate  the  difference  in  the  risk  of  com-
plications, sequelae  and  all-cause  death  between
CDI diarrhea  patients  and  patients  with  diarrhea
due to  any  other  enteric  pathogens  by  age  and
comorbidity severity.  Between  August  2008  and
August 2010,  hospitalized  patients  with  infectious
diarrhea  were  consecutively  included  in  the  study.
During  the  study  period,  every  patient  with  diar-
rhea was  tested  for  bacterial  and  viral  enteric
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her  all-cause  mortality  than  diarrhea  due  to  other  infec-
nts  with  low  comorbidities.
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athogens.  Stool  samples  were  taken  if  nurses  doc-
mented at  least  three  loose  stools  per  day  or  a
atient  reported  diarrhea.  Patients  in  the  study
ospital  were  routinely  asked  about  their  stool
haracteristics  once  daily.  As  CDI  is  not  a signiﬁcant
ause of  morbidity  and  mortality  among  hospital-
zed patients  younger  than  18  years  old  at  the  study
ospital,  hospital  patients  younger  than  18  years
ld were  excluded  from  the  study.  A  CDI  diarrhea
atient was  deﬁned  as  a  hospitalized  patient  (1)
ho had  diarrhea  and  (2)  who  had  a stool  sample
ositive for  C.  difﬁcile  toxin  A  or  B or  for  toxin-
roducing C.  difﬁcile  (i.e.,  a  CDI  study  patient)  [9].
he treatment  of  CDI  was  performed  according  to
he European  Society  of  Clinical  Microbiology  and
nfectious  Diseases  (ESCMID)  treatment  guidelines
9]. A  non-CDI  diarrhea  patient  was  a  hospitalized
atient (1)  who  had  diarrhea  and  (2)  a  stool  cul-
ure negative  for  C.  difﬁcile  but  positive  for  any
ther diarrhea-causing  pathogen  (i.e.,  a  non-CDI
tudy  patient).  Patients  with  diarrhea  for  which
o diarrhea-causing  pathogen  was  detected  after
epeated  sampling  and  testing  were  excluded  from
he study.
ata collection
he  primary  endpoints  were  pre-discharge  (death
uring  the  hospital  stay),  30-day  and  180-day  all-
ause mortality  (i.e.,  death  within  30  and  180  days,
espectively,  after  diarrhea  onset),  which  included
nfectious  diarrhea-related  deaths  (i.e.,  diarrhea  as
n underlying  or  contributing  cause  of  death)  and
eaths unrelated  to  infectious  diarrhea.
The  secondary  endpoints  were  pre-discharge
omplications  and  sequelae  at  the  30-day  follow-
p. Using  a standardized  questionnaire,  we
btained information  by  reviewing  the  patients’
edical charts  for  their  demographic  and  comor-
idity  data  (based  on  ICD-10  codes  in  discharge
etters cross-checked  with  diseases  given  in  the
edical  charts),  additional  infections  regardless
f whether  preceding  or  following  the  infectious
iarrhea, complications  related  to  the  infectious
iarrheal disease  (equal  to  the  criteria  of  severe
olitis) and  all-cause  mortality  prior  to  discharge.
he complications  used  as  the  criteria  for  severe
nteric infection  included  factors,  such  as  dehy-
ration  and  electrolyte  disorders,  paralytic  ileus,
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plostridium  difﬁcile  versus  other  enteric  pathogen
seudomembranous  colitis,  intestine  perforation,
eritonitis and  toxic  megacolon,  that  required
ntensive care  and  surgical  intervention.  The  Charl-
on Comorbidity  Index  score  was  used  to  classify
he severity  of  co-morbidities  [10]: a  score  of  <3
oints was  deﬁned  as  low,  3—5  points  as  moder-
te and  >5  points  as  severe.  In the  analyses,  two
ategories were  used:  low  comorbidity  (≤2  points)
nd moderate/severe  comorbidity  (>2  points).  The
ata on  sequelae  within  the  ﬁrst  30  days,  includ-
ng colostomy,  malabsorption  and  reactive  arthritis,
nd on  30-  and  180-day  mortality,  including  the  date
f death,  were  ascertained  by  telephone  interviews
ith the  study  patients  or  relatives.  We  also  col-
ected  data  on  diarrhea  recurrence,  deﬁned  as  the
eoccurrence  of  a  diarrheal  episode  within  2 weeks,
nd within  4  weeks  of  the  ﬁrst  diarrhea  episode
ithin 4  weeks.
tatistical analysis
ased  on  a  5%  signiﬁcance  level,  80%  power,
:1 ratio  of  non-exposed  (i.e.,  non-CDI  diarrhea
atients) to  exposed  (i.e.,  CDI  diarrhea  patients),
ssumed 10%  proportion  of  death  among  the  non-
xposed  and  ability  to  detect  a  risk  ratio  of  2.5,
he required  sample  size  was  270  study  patients,
ith 90  patients  in  the  CDI  diarrhea  group  and  180
atients  in  the  non-CDI  diarrhea  group.
The  differences  in  age  and  diarrhea  duration
etween the  CDI  and  non-CDI  patients  were  tested
sing  the  Wilcoxon  rank-sum  (Mann—Whitney)
est. Age  was  additionally  treated  as  a  dichoto-
ous variable  (≥65  vs.  <65  years).  CDI  diarrhea
atients and  non-CDI  diarrhea  patients  were
ompared with  respect  to  risk  of  complica-
ions, sequelae  and  pre-discharge,  30-day  and
80-day  mortality  by  calculating  the  relative
isk (RR)  and  the  CDI-attributable  risk  percent
%) among  the  CDI  patients  (attributable  frac-
ion [AFexp]:  100  ×  [death  riskCDI patients −  death
isknon-CDI patients]/death  riskCDI-patients)  and  the
otal study  population  (AFpop:  100  × [death  riskstudy
opulation −  death  risknon-CDI patients]/death  riskstudy
opulation)  with  95%  conﬁdence  intervals  (95%CIs).
ssociations  between  the  exposure  (CDI  diarrhea)
nd the  outcomes  were  tested  using  Pearson’s  2 or
isher’s exact  test;  p  <  0.05  was  considered  signiﬁ-
ant.  Stratiﬁed  analyses  were  performed  to  identify
onfounding  and  effect  modiﬁcations.  Strata  were
ormed by  age  (≥65  vs.  <  65  years),  comorbidity
everity (low  vs.  moderate/severe),  the  existence
f co-infections  and  the  enteric  infection  sever-
ty. Based  on  the  ﬁndings  of  the  stratiﬁed  analyses,
ultivariate analyses  by  Poisson  regression  models
ere performed.  The  preferred  regression  model
s
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as  identiﬁed  using  the  Akaike  information  crite-
ion (AIC).  The  AIC  measures  the  relative  quality
f the  model,  weighing  the  goodness  of  ﬁt  and
omplexity of  the  model.  It  is  often  used  for
odel selection.  The  Cox  multivariate  proportional
azards regression  model,  including  the  variables
f age  and  comorbidity  severity,  was  applied  to
stimate  the  adjusted  hazard  ratio  for  180-day  mor-
ality between  CDI  patients  and  non-CDI  diarrhea
atients. Kaplan—Meier  analyses  and  log-rank  tests
ere used  to  determine  the  relationship  between
he survival  endpoints  of  both  study  groups,  with
dditional  stratiﬁcation  by  age  and  comorbidity
everity. Survival  was  deﬁned  as  the  number  of days
rom the  onset  of  diarrhea  to  death  and  was  cen-
ored  at  180  days.  The  data  were  analyzed  using
tata version  10  (StataCorp  LP,  College  Station,
exas, USA).
linical microbiology
tool  specimens  obtained  from  study  patients  were
ested for  C.  difﬁcile  toxins  A and  B  using  an
nzyme-linked ﬂuorescent  assay  (ELISA;  VIDAS  sys-
em; bioMérieux,  Marcy-l’  Etoile,  France;  VIDAS
ompared  with  the  cellular  cytotoxicity  assay
CTA]: test  sensitivity  88.3%,  speciﬁcity  99.8%,
ositive  predictive  value  98.1%  and  negative  pre-
ictive value  98.4%  [package  insert]).  Stool  cultures
or C.  difﬁcile  were  performed  in  parallel  and
rrespective of  the  toxin  result.  Stool  specimens
ixed with  an  equal  volume  of  absolute  alcohol
ere inoculated  onto  cycloserine  cefoxitin  fructose
gar (CCFA)  (Oxoid,  Cambridge,  UK)  and  incu-
ated at  36  ±  1 ◦C  in  an  anaerobic  atmosphere  (<1%
xygen  and  ≥13%  carbon  dioxide;  Becton  Dickin-
on, Heidelberg,  Germany)  for  48  h.  Suspected  C.
ifﬁcile colonies  were  conﬁrmed  by  testing  for  glu-
amate dehydrogenase  (GDH)  using  a  latex  slide
gglutination  test  (C.  difﬁcile  Agglutination  Test
it; Microgen,  Camberley,  UK).  The  demonstration
f toxin  production  was  performed  with  GDH-
ositive C.  difﬁcile  colonies  using  ELFA  (bioMérieux)
‘‘toxigenic culture  method’’).  A  negative  result  for
oxigenic C.  difﬁcile  was  conﬁrmed  only  when  the
esults of  both  toxin  tests  were  negative.  In  the  case
f unclear  results,  the  entire  procedure  of  stool
ampling  and  testing  was  repeated.
In parallel,  stool  cultures  were  performed  for
ny bacterial  diarrhea-causing  pathogens,  including
almonella,  campylobacter,  shigella,  shigatoxin-
roducing E.  coli,  Y.  enterocolitica  and  Aeromonas
sp. [11], and  tested  for  the  most  prevalent
iarrhea-causing  viruses  in  Austria,  including  ade-
ovirus, norovirus,  rotavirus  and  astrovirus,  using
LISA or  RT-PCR  as  described  elsewhere  [12].
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Figure  1  Pathogen-speciﬁc  diarrhea  cases  (blue  bar),  pathogen-speciﬁc  deaths  (patterned  bar),  pathogen-speciﬁc
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The  study  was  approved  by  the  ethics  commit-
tee of  the  Vienna  Association  of  Hospitals  (Wiener
Krankenanstaltenverbund).
Results
Study population
Between  August  2008  and  August  2010,  270
hospitalized patients  with  laboratory-conﬁrmed
infectious  diarrhea  were  included  in  the  study
cohort, including  90  CDI  diarrhea  patients  and  180
non-CDI diarrhea  patients.  In  the  non-CDI  diar-
rhea patients,  norovirus  was  the  most  common
enteric pathogen  (55.0%),  followed  by  campy-
lobacter (26.7%),  adenovirus  (11.1%),  non-typhoidal
salmonella (10.0%)  and  rotavirus  (5.6%).  Fig.  1 dis-
plays the  study  patients  and  fatal  cases  by  enteric
pathogen  and  pathogen-speciﬁc  pre-discharge  case
fatality (Fig.  1).
The  characteristics  of  the  total  study  population
and of  the  CDI  diarrhea  patient  group  compared
with the  non-CDI  diarrhea  patient  group  are  given
in Table  1.  Among  the  270  study  patients,  66  (24.5%)
had  an  additional  infection,  including  urinary  tract
r
2
3
pate  (i.e.  pathogen-speciﬁc  deaths/cases  in  %).
nfections  (28/66;  42.4%),  respiratory  tract  infec-
ions (24/66;  36.4%)  and  other  infections  (14/66;
1.0%).
isk of complications and 30-day sequelae
etween CDI and other infectious diarrhea
igns  of  severe  infections  occurred  in  25.6%  of  CDI
iarrhea  patients  (23/90)  and  33.9%  of  non-CDI
iarrhea  patients  (61/180)  (RR  =  0.75,  95%CI:
.50—1.13). Dehydration  and  electrolyte  disorders,
hich  were  the  most  common  manifestation
f severe  enteric  infection  in  our  study  cohort
82/270; 30.4%),  were  observed  in  23.3%  (n  =  21)  of
DI patients  and  33.9%  (n  =  61)  of  non-CDI  diarrhea-
atients  without  a signiﬁcant  difference  (RR  =  0.69,
5%CI: 0.45—1.05).  Pseudomembranous  colitis  was
bserved in  two  CDI  patients,  and  intestinal  per-
oration  was  observed  in  one  CDI  patient  and  one
on-CDI  patient.  There  was  no  surgical  treatment
r intensive  care  required  as  the  two  patients  with
erforation  had  a rapid  fatal  course.  The  RR  of  diar-
hea recurrence  was  8.9  within  2  weeks  (ad95%CI:
.9—27.3) and  11.4  within  4 weeks  (ad95%CI:
.9—33.9) in  CDI  patients  compared  with  non-CDI
atients, when  adjusted  for  age,  comorbidity
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Table  1  Characteristics  of  the  total  study  population  (N  =  270),  of  the  CDI  patient  group  (n  =  90)  and  of  the  non-CDI
diarrhea  patient  group  (n  =  180).
Characteristics  of  study  patients  Total
N  =  270
CDI
diarrhea
n  =  90
Non-CDI
diarrhea
n =  180
p
Sex  =  female 187
(69.3%)
60
(66.7%)
127
(70.6%)
0.5139**
Median  age  (range)  77.5
(18—102)
76.5
(21—91)
78.0
(18—102)
0.2027*
Age  ≥65  years  196/270
(72.6%)
69/90
(76.7%)
127/180
(70.6%)
0.2886**
Moderate/severe  comorbidity  54/270
(20.0%)
26
(28.9%)
28
(15.6%)
0.0098**
Health-care  associated  171
(63.3%)
80
(88.9%)
91
(50.6%)
<0.0001**
Duration  (d)  of  diarrhea**** (mean,  min;  max)  7.6  days
(1—82)
12.5
days
(1—82)
5.5  days
(1—42)
<0.0001*
Age  group  <65  years N =  74  N  =  21  N  =  53
Moderate/severe  comorbidity 9/74
(12.2%)
6/21
(28.6%)
3/53
(5.7%)
0.0131***
Age  group  ≥65  years  N  =  196  N  =  69  N  =  127
Moderate/severe  comorbidity  45/196
(3.0%)
20/69
(29.0%)
25/127
(19.7%)
0.1392**
* t-test.
** Chi-square test.
*** Fisher’s exact test.
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t**** Duration of ﬁrst diarrhea episode.
everity  and  presence  of  additional  infections.
ecurrent diarrhea  episodes  between  2  and  4
eeks occurred  in  ﬁve  CDI  patients  and  no  non-CDI
atients.
isk of all-cause mortality between CDI and
ther infectious diarrhea
he  pre-discharge,  30-day  and  180-day  mortality
mong all  study  patients  was  11.5%,  10.2%  and
0.6%,  respectively  (Tables  2  and  3, Fig.  2).  A
ogistic  regression  revealed  that  older  age,  severe
omorbidities and  additional  infections  were  inde-
endent risk  factors  for  pre-discharge  and  30-day
eath  for  the  total  study  population  whereas  severe
nteric  infection  was  not  an  independent  mortality
isk  factor.  The  pre-discharge,  30-day  and  180-day
ortality  risk  was  20.0%,  17.0%  and  42.3%,  respec-
ively,  in  the  CDI  diarrhea  patients  and  7.2%,  6.7%
nd 22.5%,  respectively,  in  the  non-CDI  diarrhea
atients.
The risk  of  pre-discharge  all-cause  mortality
or the  CDI  diarrhea  patients  was  approximately
hree times  higher  than  that  for  the  non-CDI
iarrhea patients,  reﬂecting  a  mortality  fraction
p
d
rttributable  to  CDI  among  all  study  patients  (includ-
ng CDI  and  non-CDI  diarrhea  patients)  of  37.1%
Table  2).  After  adjustment  for  age,  comorbid-
ty severity  and  additional  infections,  the  RR  for
re-discharge  mortality  in  CDI  patients  was  2.15
ad95%CI:  1.04—4.45)  compared  with  non-CDI  diar-
hea patients,  resulting  in  an  adjusted  mortality
raction attributable  to  CDI  of  29.7%  (ad95%:
.1%—43.1%) for  the  study  population  (data  not
hown).
Among  the  study  population  with  low  comor-
idities or  without  additional  infections,  CDI  was
ssociated  with  3.7  and  6.1  times  higher  risks,
espectively,  of  pre-discharge  all-cause  mortality
han  non-CDI  diarrhea.  In  the  patients  younger  than
5 years  old,  3 of  the  21  CDI  diarrhea  patients  and
o non-CDI  diarrhea  patient  died  prior  to  discharge.
mong the  patients  with  additional  infections  and
hose with  more  severe  comorbidities,  there  were
o signiﬁcant  differences  in  the  pre-discharge  mor-
ality risk  between  the  CDI  and  non-CDI  diarrhea
atients (Table  2).
The  30-day  all-cause  mortality  risk  in  the  CDI
iarrhea patients  compared  with  the  non-CDI  diar-
hea patients  was  2.5  times  higher  and  decreased
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Table  2  All-cause,  pre-discharge  mortality  among  CDI  patients  (N  =  90)  compared  with  non-CDI  diarrhea  patients  (N  =  180)  by  relative  risk  (RR),  CDI-attributable
fraction  of  mortality  among  CDI  diarrhea  patients  (AFexp) and  CDI-attributable  fraction  of  mortality  among  the  total  study  population  (AFpop),  stratiﬁed  by  comorbidity
severity,  age  and  presence  of  additional  infection.
Pre-
discharge
mortal-
ity
Total  N  =  270  CDI  N  =  90  Non-CDI
diarrhea
N  =  180
RR  (95%CI)  P  AFexp (95%CI)  AFpop (95%CI)
n/N  (%) n/N  (%) n/N  (%)
Crude  31/270  (11.5%) 18/90  (20.0%) 13/180
(7.2%)
2.77 (1.42—5.40) 0.0019 63.9%  (29.6%,  81.5%) 37.1%  (12.4%,  61.8%)
Stratiﬁed  by  comorbidity  severity
Low  18/216  (8.3%)  11/64  (17.2%)  7/152
(4.6%)
3.73 (1.52—9.19)  0.0022  73.2%  (34.0%,  89.1%)  44.7%  (13.9%,  75.6%)
moderate/severe13/54  (24.1%)  7/26  (26.9%)  6/28
(21.4%)
1.26 (0.49—3.25)  0.6370  20.4%  (−106.0,  69.2%)  11.0%  (−34.7%,  56.6%)
Stratiﬁed  by  age  Group
<65  3/74  (4.1%) 3/21  (14.3%) 0/53
(0%)
— 0.0205  100%  100%
≥65 28/196  (14.3%) 15/69  (21.7%)  13/127
(10.2%)
2.12 (1.07—4.20)  0.0279  52.9%  (6.8%,  76.2%)  28.3%  (1.9%,  54.8%)
Stratiﬁed  by  additional  infection
No  18/204  (8.8%) 13/61  (21.3%) 5/143
(3.5%)
6.10 (2.27—16.35)<0.0001  83.6%  (56.0%,  93.9%)  60.4%  (31.7%,  89.1%)
Yes 13/66  (19.7%) 5/29  (17.2%)  8/37
(21.6%)
0.80 (0.29—2.18)  0.6570  —  —
Clostridium
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Table  3  All-cause,  30-day  mortality  among  CDI  patients  (N  =  90)  compared  with  non-CDI  diarrhea  patients  (N  =  180)  by  relative  risk  (RR),  CDI-attributable  fraction  of
mortality  risk  among  CDI  diarrhea  patients  (AFexp)  and  CDI-attributable  risk  fraction  of  mortality  among  the  total  study  population  (AFpop),  stratiﬁed  by  comorbidity
severity,  age  and  presence  of  additional  infection.
30-day
mortal-
ity
Total  N  =  266a CDI  N  =  88 Non-CDI
diarrhea
N  =  178
RR  (95%CI) P AFexp (95%CI) AFpop (95%CI)
n/N  (%)  n/N  (%)  n/N  (%)
Crude  27/266  (10.2%)  15/88  (17.0%)  12/178
(6.7%)
2.53  (1.24—5.17)  0.0088  60.4%  (19.2%Stratiﬁed  by80.6%)  33.6%  (6.9%-60.2%)
Stratiﬁed  by  comorbidity  severity
Low  17/212  (8.0%)  9/62  (14.5%)  8/150
(5.3%)
2.72  (1.10—6.73)  0.0251  63.3%  (9.2%,  85.1%)  33.5%  (1.3%,  65.7%)
moderate/severe10/54  (18.5%)  6/26  (23.1%)  4/28
(14.3%)
1.62  (0.51—5.09)  0.4945  38.1%  (−94.9%,  80.3%)  22.9%  (−30.5%,  76.2%)
Stratiﬁed  by  age  group
<65  3/72  (4.2%)  3/21  (14.3%)  0/51  (0%)  —  0.0223  100%  100%
≥65  24/194  (12.4%)  12/67  (17.9%)  12/127
(9.4%)
1.90  (0.90—3.99)  0.0888  47.2%  (−11.0%,  74.9%)  23.6%  (−5.0%,  52.2%)
Stratiﬁed  by  additional  infection
No  15/201  (7.5%)  10/59  (16.9%)  5/142
(3.5%)
4.81  (1.72—13.48)  0.0010  79.2%  (41.8%—92.6%)  52.8%  (20.0%,  85.6%)
Yes  12/65  (18.5%)  5/29  (17.2%)  7/36
(19.4%)
0.89  (0.31—2.50)  0.8200  —  —
a For 4 study patients data on 30-day outcome not available.
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iFigure  2  Kaplan—Meier  survival  estimates  in  CDI  diarrh
severity.
to  2.0  (ad95%CI:  0.92—4.35)  after  adjustments  for
age, comorbidity  severity  and  additional  infections.
Among  the  patients  older  than  65  years,  the  30-
day mortality  risk  no  longer  signiﬁcantly  differed
between the  CDI  and  non-CDI  diarrhea  patients.  The
results of  the  stratiﬁed  analyses  of  the  30-day  mor-
tality risk  by  comorbidity  severity  and  additional
infection were  are  similar  to  the  ﬁndings  on  the
pre-discharge  mortality  risk  (Table  3).  After  strat-
iﬁcation  by  enteric  infection  severity  as  deﬁned
above, no  difference  in  the  30-day  mortality  risk
was observed  between  the  two  diarrhea  groups  in
those patients  with  severe  enteric  infection  (data
not shown).  Among  the  patients  with  mild  enteric
infection, a  signiﬁcant  difference  was  observed
only among  those  ≥65  years  old  and  with  low
co-morbidity, with  CDI  diarrhea  patients  being  at
greater risk  of  30-day  death  (RR:  3.55,  CI:  1.12,
11.30).
A regression  model,  including  the  covariates
of age,  comorbidity  severity  and  an  interaction
term between  the  exposure  status  (CDI/non-CDI
diarrhea) and  the  covariate  additional  infections,
revealed that  study  patients  without  additional
infections had  a  RR  for  30-day  mortality,  adjusted
for age  and  comorbidities,  of  3.98  (ad95%CI:
1.35—11.77) for  CDI  diarrhea  compared  with  non-
CDI diarrhea.  The  adjusted  RR  of  30-day  death  was
(
1
ind  non-CDI  patients  stratiﬁed  by  age  and  comorbidity
.77  (ad95%CI:  1.38—16.46)  when  comparing  the
DI patients  with  additional  infections  with  non-CDI
atients  without  additional  infections.  The  highest
R for  30-day  death  was  observed  in  the  non-CDI
atients with  additional  infections  compared  with
he non-CDI  patients  without  additional  infections
adRR: 5.55;  95%CI:  1.74—17.71)  (data  not  shown).
The data  on  all-cause  180-day  mortality  were
vailable  for  71  CDI  patients  and  102  non-CDI
atients. The  crude  180-day  mortality  was  slightly
igher (RR:  1.87)  in  the  CDI  patients  than  in  the  non-
DI diarrhea  patients.  The  ﬁndings  of  the  stratiﬁed
nalysis  on  180  day-mortality  by  co-morbidity  and
ge are  given  in  Fig.  2. As  already  observed  in  the
tratiﬁed  comparisons  of  pre-discharge  and  30-day
ortality  risk  between  the  CDI  diarrheal  and  non-
DI diarrheal  patients,  we  found  signiﬁcantly  higher
80-day mortality  risk  only  among  the  CDI  patients
ith low  comorbidity  or  an  age  younger  than  65
ears compared  with  the  non-CDI  patients  of  the
ame strata.  A  Cox  regression  analysis,  adjusted  for
ge and  comorbidity  severity,  revealed  a 2.25-fold
95%CI:  1.30—3.91)  higher  hazard  of  180-day  death
n the  CDI  patients  than  in  the  non-CDI  patients
data not  shown).
In the  Kaplan—Meier  analyses,  the  estimated
80-day survival  probability  was  signiﬁcantly  lower
n the  CDI  patients  than  in  the  non-CDI  patients  (61%
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s.  83%;  log  rank  p  = 0.0003).  The  Kaplan—Meier
lots, stratiﬁed  by  age  and  comorbidity  severity,
re displayed  in  Fig.  2  (Fig.  2  plus  integrated  table
n 180-day  mortality  analyses).  The  stratiﬁed  sur-
ival probability  analyses,  using  the  log-rank  test,
onﬁrmed  the  results  of  the  180-day  mortality  anal-
ses (Fig.  2).
iscussion
e  investigated  the  risk  of  complications,  seque-
ae and  pre-discharge,  30-day  and  180-day  all-cause
ortality  among  adult  hospital  patients  with  diar-
hea due  to  CDI  compared  with  adult  hospital
atients with  diarrhea  due  to  other  infectious
gents. Among  the  non-CDI  diarrhea  patients,
orovirus was  the  dominant  pathogen  (accounting
or 55%  of  all  non-CDI  diarrheal  patients),  fol-
owed  by  campylobacter,  adenovirus,  non-typhoidal
almonella and  rotavirus.  Jansen  et  al.  described
 similar  frequency  distribution  of  the  etiological
athogens of  acute  gastroenteritis  in  adult,  hospi-
alized  patients  at  a  large  German  hospital  [13].
Overall, the  risk  of  developing  at  least  one  com-
lication  did  not  differ  signiﬁcantly  between  the
wo diarrhea  patient  groups.  The  most  common
omplication in  the  CDI  diarrheal  patients  and  also
n the  non-CDI  diarrheal  patients  was  dehydration
ith electrolyte  disorders,  as  previously  found  in
DI hospital  patients  in  the  U.S.,  and  the  frequency
id not  differ  signiﬁcantly  between  the  CDI  and  non-
DI patients  [14].  Our  ﬁndings  on  the  low  rates  of
seudomembranous  colitis  and  intestine  perfora-
ion  and  on  the  absence  of  toxic  megacolon  and
eritonitis  among  our  CDI  study  patients  are  sim-
lar to  the  ﬁndings  of  Lucado  et  al.  Among  the
DI patients,  the  recurrence  of  diarrhea  within  4
eeks following  a  previous  diarrhea  episode  was
n accordance  with  other  recently  reported  rates,
hich ranged  between  16%  and  25%  [15,16]. Com-
ared with  the  non-CDI  diarrheal  patients,  the
DI patients  were  approximately  11  times  more
ikely  to  experience  diarrhea  recurrence  within  4
eeks, independent  of  age,  comorbidities  and  addi-
ional infections.  Recurrent  diarrhea  within  2  and  4
eeks occurred  only  in  CDI  patients.  These  ﬁndings
ere expected  as  diarrhea  reappearance  is  rarely
bserved  for  non-CDI  infectious  diarrheal  diseases
17—19].
Of all  pre-discharge  deaths  in  our  study,  CDI
ccounted for  58%,  norovirus  infection  for  35.5%
nd Campylobacter  spp.  and  adenovirus  for  3.2%
ach. Among  non-CDI  diarrhea  patients,  norovirus
iarrhea was  associated  with  the  highest  mortality.
hese data  are  in  accordance  with  the  U.S.  National
C
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enter  for  Health  Statistics  data,  which  recently
ecognized C.  difﬁcile  as  the  ﬁrst  and  norovirus
s the  second  leading  causes  of  gastroenteritis-
ssociated  deaths  [1].
As expected,  we  found  considerably  higher  pre-
ischarge,  30-day  and  180-day  all-cause  mortality
isks among  the  CDI  patients  than  the  non-CDI
iarrheal patients  (20.0%,  17.0%  and  42.3%  versus
.2%, 6.7%  and  22.5%,  respectively).  Our  ﬁndings
n the  all-cause  mortality  in  patients  with  CDI  are
n accordance  with  the  CDI  literature  of  the  past
0 years.  The  pre-discharge  CDI-associated  mortal-
ty is  reported  to  be  between  5%  and  21.5%  and  to
otentially  be  as  high  as  35%  among  patients  with
ulminant  CDI  [20—22].  The  30-day  all-cause  mor-
ality in  healthcare-acquired  CDI  patients  ranges
etween  2%  and  42%,  as  reported  in  a European
ystematic review  by  Wiegand  et  al.  [23]. The  Euro-
ean hospital-based  surveillance  study  by  Bauer
t al.  reported  a 90-day  mortality  of 22%,  and  a U.S.
etrospective  cohort  study  of  nonsurgical  CDI  inpa-
ients observed  a 180-day  all-cause  mortality  of  38%
24,25]. The  wide  range  of  all-cause  pre-discharge,
0-day and  180-day  mortality  rates  observed  over
he past  10  years  in  CDI  patients  may  be  due  to
he different  CDI  cohorts  studied.  Although  most
tudies  report  all-cause  mortality  by  age  of  the  CDI
ohort, few  authors  took  into  account  the  possible
onfounding or  modifying  effects  of  comorbidities
3,6,25,26], and  no  study  considered  the  effect  of
dditional infections.
Our  cohort  study  prospectively  investigated  the
ifference  in  the  clinical  outcome  between  inpa-
ients with  CDI  diarrhea  and  inpatients  with  other
nfectious  diarrhea,  considering  the  possible  effects
f age,  comorbidities  and  additional  infections.
As expected,  compared  with  the  non-CDI  diar-
hea patients,  the  CDI  diarrhea  patients  had  a  2.2
nd 2.0  times  higher  risk  of  all-cause  death  prior
o discharge  and  within  the  ﬁrst  30  days,  respec-
ively, when  adjusted  for  age,  comorbidities  and
dditional  infections.  A  different  study  at  the  same
ospital  by  Wenisch  et  al.  compared  CDI  patients
ith all  other  hospital  patients  and  found  a slightly
igher  adjusted  RR  of  pre-discharge  all-cause  death
RR: 2.7),  which  is  likely  due  to  the  more  het-
rogeneous comparison  group  than  our  comparison
roup [27]. A  recently  published  study  by  Kuijper
t al.  investigated,  in  a multi-center  cohort  study,
he 30-day  mortality  rate  in  CDI  patients  compared
ith that  in  patients  without  diarrhea  and  with
atients  with  non-CDI  diarrhea  (a negative  test  for
. difﬁcile  toxins).  Similar  to  the  Austrian  ﬁnd-
ngs, the  CDI  patients  compared  with  the  patients
ithout diarrhea  were  2.5  times  more  likely  to  die
ithin the  ﬁrst  30  days,  when  adjusted  for  age,
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sex  and  comorbidities.  When  compared  with  the
diarrheal  patients  with  C.  difﬁcile  toxin-negative
fecal samples,  the  authors  observed  a smaller  30-
day mortality  rate  difference  than  we  found  in  the
current study.  The  explanations  might  include  the
failure to  identify  all  CDI  cases  among  the  diarrhea
patients due  to  the  low  sensitivity  of  the  C.  dif-
ﬁcile toxin  detection  assay  used,  as  stated  by  the
author [28].  In  our  study,  such  misclassiﬁcation  bias
is rather  unlikely;  for  all  diarrhea  patients,  a stool
culture  for  C.  difﬁcile  was  performed  in  parallel
with and  irrespective  of  the  stool  toxin  result.  The
demonstration  of  toxin  production  was  conducted
by the  toxigenic  culture  method.  A  negative  result
for toxigenic  C.  difﬁcile  was  conﬁrmed  only  when
the results  of  both  toxin  tests  were  negative.
Dubberke  et  al.  reported  an  adjusted  180-day
hazard ratio  (HR)  of  1.2  for  CDI  patients  compared
with all  non-CDI,  non-surgical  inpatients  [25]. The
180-day HR  we  observed  for  the  CDI  patients  com-
pared  with  the  non-CDI  patients  was  approximately
twice as  high,  which  is  likely  due  to  the  inclusion  of
surgical patients  in  our  study  cohort.
As expected,  the  pre-discharge,  30-day  and
180-day mortality  risks  increased  with  age,  comor-
bidity  severity  and  additional  infections  in  both
study groups.  In  the  CDI  diarrhea  patients,  the
pre-discharge  and  30-day  mortality  risks  increased
from age-group  <65  years  to  age-group  ≥65  years
by more  than  7%  and  3%,  respectively.  In  a  system-
atic review,  Bloomﬁeld  et  al.  recently  conﬁrmed
age as  a  useful  risk  marker  for  all-cause  CDI
mortality in  the  general  hospital  population  [29].
However, in  the  non-CDI  diarrhea  patients,  the
increase  in  the  pre-discharge,  30-day  and  180-day
mortality  risks  by  age  was  more  pronounced  than
in the  CDI  diarrhea  patients.  Hence,  we  observed
a small  or  even  insigniﬁcant  difference  in  the
mortality risks  between  the  CDI  and  non-CDI
diarrhea patients  aged  ≥65  years  compared  with
the large  mortality  risk  difference  between  CDI
and non-CDI  diarrheal  patients  aged  <65  years.  This
phenomenon  was  also  found  in  the  stratiﬁcation
by comorbidity  severity.  The  all-cause  mortality
risks were  signiﬁcantly  higher  for  CDI  than  for
non-CDI only  among  those  diarrhea  patients  with
low comorbidities.  The  in-hospital  mortality  study
by Wenisch  et  al.  that  compared  CDI  patients
with all  other  hospital  patients  also  found  the
highest CDI-attributable  mortality  fractions  among
patient-groups  younger  than  65  years  or  with  low
comorbidities  [27].  The  smaller  effect  of  CDI  on  the
mortality  risk  among  inpatients,  who  were  older  or
with more  severe  comorbidities  could  be  explained
by the  high  prevalence  of  fatal  underlying  dis-
eases that  have  a  greater  impact  on  the  all-cause
t
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ortality  risk  than  CDI  among  these  patient
roups.
Among patients  with  an  infection  in  addition
o the  enteric  infection  under  study,  the  mortal-
ty risk  of  the  CDI  diarrhea  patients  was  no  longer
igniﬁcantly  different  from  that  of  the  non-CDI  diar-
hea patients.  A  regression  model  indicated  a  larger
odiﬁcation  of  the  effect  of  enteric  infection  on
he mortality  risk  by  the  exposure  to  an  additional
nfection for  non-CDI  diarrhea  patients  than  for
DI diarrhea  patients.  Multiple,  simultaneous  infec-
ions can  affect  the  host  more  severely  than  a single
nfection  due  to  mutualistic  pathogen—pathogen
nteractions  [30]. This  type  of  pathogen  interac-
ion  more  likely  occurred  in  the  non-CDI  diarrhea
atients, in  whom  the  shorter  hospital  stay  dura-
ion made  a  simultaneous  additional  infection  more
onceivable.  In  the  CDI  patients,  the  other  infection
ight  have  more  likely  preceded  the  infection  with
. difﬁcile.
Our  cohort  study  has  a  few  limitations.  One
ould argue  that  the  ‘‘non-CDI  diarrhea’’  group  in
ur study  is  too  different  from  the  CDI  diarrhea
roup in  terms  of  the  factors  associated  with  both
he host  and  the  diarrhea-causing  pathogens.  The
tratiﬁed analyses  by  age  and  comorbidity  should
ufﬁciently  control  for  differences  in  the  distribu-
ion of  relevant  host  risk  factors  for  death.  The
igher  proportion  of  HA-cases  in  the  CDI  patients
89%) than  in  the  non-CDI  patients  (51%)  should  not
atter when  comparing  risks  of  mortality;  there  is
urrently no  convincing  evidence  available  to  claim
igher virulence  of  hospital  strains  of  C.  difﬁcile
ompared with  community  strains.  Using  all-cause
eath (pre-discharge,  within  30  and  within  180
ays) as  a  measure  for  attributing  mortality  to  CDI
ight be  inaccurate.  Autopsy  is  the  most  accurate
ethod to  determine  the  cause  of  death  but  is  not
easible  for  wide-scale  public  reporting.  Hota  et  al.
nalyzed three  measures  for  attributing  death  to
DI: death  certiﬁcate,  death  within  30  days  of  CDI
nd a  panel  review  process.  Their  ﬁndings  support
he use  of  death  within  30  days  as  a speciﬁc  marker
or CDI-attributable  death  and  consider  this  method
o be  more  feasible  than  panel  review  and  more
ccurate  than  death  certiﬁcate  data  [31].
onclusions
DI  was  again  found  to  be  a major  contributor
o death  among  hospitalized  patients  with  infec-
ious diarrhea.  When  stratifying  the  patient  cohort
y risk  factors  for  death,  we  observed  among  the
iarrheal  patients  with  an  older  age,  more  severe
omorbidities or  additional  infections,  slight  or
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[lostridium  difﬁcile  versus  other  enteric  pathogen
on-signiﬁcant  differences  in  the  all-cause  mortal-
ty risk  between  patients  with  CDI  and  those  with
ther  enteric  infections.  In  contrast,  diarrhea  inpa-
ients with  low  comorbidities,  who  were  younger
han 65  years  or  without  additional  infections  were
etween  2.7  and  4.8  times  more  likely  to  die  within
0 days  of  diarrhea  onset  when  infected  with  C.
ifﬁcile than  with  other  enteric  pathogens.
Our  study  highlights  the  importance  of  stratiﬁed
nalyses by  age  groups  and  co-morbidity  severity
hen  estimating  the  impact  of  CDI  on  the  mor-
ality risk.  Among  diarrhea  inpatients  with  low
omorbidities  or  who  were  younger  than  65  years,
e found  fractions  of  30-day  all-cause  mortality
ttributable to  CDI  of  100%  and  34%,  respectively;
owever, among  the  diarrhea  patients  older  than
5 years  or  with  severe  comorbidities,  the  con-
ribution of  CDI  to  the  30-day  mortality  risk  was
nsigniﬁcant.
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